( EuronextBrussels:THR )

News from ThromboGenics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jun 08, 2016, 11:40 ET ThromboGenics Receives US FDA Approval for New 'Already-Diluted' Formulation of JETREA®

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for back of the eye disease, today...


May 13, 2016, 01:30 ET ThromboGenics Business Update - Q1 2016

Developing Novel Medicines Targeting Diabetic Eye Disease    Highlights  - ThromboGenics is focused on developing novel...


Apr 27, 2016, 02:00 ET New Ocriplasmin Research Findings Presented

New Data Confirm Appropriate Patient Selection Leads to Improved Treatment Outcomes, With no new Safety Signals Observed  ThromboGenics NV...


Mar 01, 2016, 02:00 ET ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments...


Jan 13, 2016, 01:30 ET ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Assessing the potential of ocriplasmin to reduce risk of disease progression from NPDR to sight-threatening Proliferative Diabetic Retinopathy...